HIGHLIGHTS
SUMMARY
A recent systematic review and meta-analysis including 8 papers and 1236 patients with cancer concluded that a higher circulating level of sCD163 was significantly correlated with shorter OS and progression-free survival in patients with different types of cancer. The aim of this biomarker study was to test the hypotheses that circulating sCD163 levels are elevated in patients with PDAC compared to healthy subjects and that high plasma sCD163 is associated with poor prognosis in patients with PDAC. This confirms the hypothesis that circulating sCD163 levels are elevated in patients with PDAC and . . .
If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.